This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Baxter-Dorizoe Ink Deal to Expand Generic Injectables Line
by Zacks Equity Research
Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company, recently signed an agreement with India-based Dorizoe Lifesciences for expansion of its generic injectables pipeline.
CONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Utica, NY-based leading medical technology player, CONMED Corporation (CNMD) rallied to a new 52-week high of $52.79 on Jun 13, closing a little lower at $52.49.
5 Top Performing Efficient Stocks to Buy Now
by Tirthankar Chakraborty
A favorable efficiency level provides impressive returns as it is positively correlated with the company's price performance
IDEXX Laboratories Global Growth Solid amid Currency Woes
by Zacks Equity Research
On May 29, we issued an updated research report on leading molecular diagnostic company, IDEXX Laboratories, Inc. (IDXX).
IDEXX (IDXX) Up 3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
IDEXX (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects
by Zacks Equity Research
On May 22, IDEXX Laboratories, Inc. (IDXX), a leading manufacturer of products and services primarily for the companion animal veterinary, was raised by a notch to a Zacks Rank #2 (Buy).
Why IDEXX Laboratories (IDXX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX Laboratories (IDXX).
IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.
IDEXX Laboratories (IDXX) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
IDEXX's first-quarter earnings per share came in at 77 cents, an increase of 51% year-over-year on reported basis. On a constant currency basis, this figure improved 53% year over year.
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
Investors may buy IDEXX Laboratories (IDXX) Ahead of Earnings depending on its decent Zacks Rank and earnings ESP in the positive territory.
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report first-quarter 2017 results on Apr 28, before the opening bell.
Becton (BDX) Gets FDA 510(k) for New Flow Cytometer System
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.
Mazor Expects Higher Q1 Revenue, Receives Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report record first-quarter 2017 revenue of approximately $11.5 million compared with only $6.4 million in the year-ago quarter.
IDEXX Laboratories' CAG Revenues Solid, Competition Rife
by Zacks Equity Research
On Apr 5, we issued an updated research report on Delaware NJ-based IDEXX Laboratories, Inc. (IDXX).
Teleflex (TFX) Acquires Medical Device Provider Pyng Medical
by Zacks Equity Research
Teleflex Inc. (TFX), a global provider of medical technologies, announced that it has acquired Pyng Medical Corporation.
Becton, Dickinson Takes Over Caesarea Medical Electronics
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has acquired Caesarea Medical Electronics.
5 Stocks that Outperformed the S&P 500 in Q1
by Zacks Equity Research
First quarter was quite impressive and we have selected five top-ranked stocks that surpassed the S&P 500 index during the period.
Varian (VAR) Eclipse Software Tops in International Studies
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that its Eclipse treatment planning software has topped in two competitive international plan studies.
PAREXEL (PRXL) Launches Sensor for Clinical Trial Market
by Zacks Equity Research
PAREXEL International Corporation (PRXL), a global biopharmaceutical services company and provider of clinical research and logistics, recently announced the launch of its patient sensor solution.
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, reported adjusted earnings of 19 cents per share in the third quarter of fiscal 2017.
New Zacks Rank Strong Buy Stocks Breaking to Highs
by David Bartosiak
Today???s Daily Dive included a brief overview of the stellar action on crude oil, including intermediate term targets for the contract.
Envision (EVHC) Teams Up with Lyft to Focus on Transportation
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) recently announced that it has teamed up with on-demand transportation service provider Lyft.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
On Mar 29, we issued an updated research report on North Kansas City, MO-based Cerner Corporation (CERN) ??? a leading global provider of healthcare information technology solutions (HCIT).
Here's Why You Should Steer Clear of Mednax (MD) for Now
by Zacks Equity Research
Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.